LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Kodu・Aktsiate loetelu・SCYNEXIS Inc

SCYNEXIS Inc

Suletud

0.79 -1.25

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.76

Max

0.81

Põhinäitajad
By Trading Economics
Sissetulek	-1.7M -8.6M
Müük	-1M 334K
Kasumimarginaal	-2,572.156
Töötajad	28
EBITDA	9.4M -186K

Turustatistika
By TradingEconomics
Turukapital	4.7M 31M
Eelmine avamishind	2.04
Eelmine sulgemishind	0.79

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

0.9307 / 0.9907 Toetus ja vastupanu

SCYNEXIS Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. veebr 2026, 23:47 UTC

Kuumad aktsiad

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11. veebr 2026, 22:59 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Grab Holdings to Buy U.S.-Based Stash Financial

11. veebr 2026, 23:54 UTC

Tulu

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11. veebr 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

11. veebr 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11. veebr 2026, 23:49 UTC

Tulu

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11. veebr 2026, 23:45 UTC

Tulu

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11. veebr 2026, 23:42 UTC

Tulu

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11. veebr 2026, 23:41 UTC

Tulu

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11. veebr 2026, 23:40 UTC

Tulu

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11. veebr 2026, 23:35 UTC

Market Talk

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11. veebr 2026, 23:18 UTC

Market Talk

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11. veebr 2026, 23:14 UTC

Market Talk

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11. veebr 2026, 22:59 UTC

Tulu

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11. veebr 2026, 22:59 UTC

Tulu

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11. veebr 2026, 22:59 UTC

Tulu

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11. veebr 2026, 22:58 UTC

Tulu

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11. veebr 2026, 22:57 UTC

Tulu

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11. veebr 2026, 22:54 UTC

Tulu

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11. veebr 2026, 22:53 UTC

Tulu

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11. veebr 2026, 22:47 UTC

Tulu

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11. veebr 2026, 22:47 UTC

Tulu

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11. veebr 2026, 22:23 UTC

Tulu

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11. veebr 2026, 22:22 UTC

Tulu

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11. veebr 2026, 22:22 UTC

Tulu

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11. veebr 2026, 22:19 UTC

Tulu

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11. veebr 2026, 22:18 UTC

Tulu

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11. veebr 2026, 22:18 UTC

Tulu

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11. veebr 2026, 22:18 UTC

Tulu

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11. veebr 2026, 22:16 UTC

Tulu

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Võrdlus sarnastega

Hinnamuutus

SCYNEXIS Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi SCYNEXIS Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9307 / 0.9907Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.